Auven Therapeutics Management

Auven Therapeutics is a global private equity firm that utilizes a unique "product development" model to advance promising therapeutic assets through clinical trials. Founded by industry veterans Stephen Evans-Freke and Dr. Peter B. Corr, the firm acquires majority stakes in drug candidates and manages their development until they reach a value-inflection point, such as regulatory approval or a strategic sale. Auven's portfolio has spanned diverse therapeutic areas including oncology, ophthalmology, and women's health. The firm is notably responsible for the founding and development of ADC Therapeutics and the successful exit of Spirogen to AstraZeneca.